Sarepta Therapeutics stock: Deutsche Bank lifts rating to Hold
Published on 11/15/2026 at 13:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat Deutsche Bank changed
- Deutsche Bank raised Sarepta's rating from Sell to Hold after the third-quarter report.
- The bank cited improved fundamentals and a more constructive view of the company's pipeline funding strategy.
Deutsche Bank upgraded Sarepta Therapeutics from Sell to Hold on November 10, 2026, and raised its price target to 18 US dollars from 14 US dollars. Markets Insider reported the analyst action, which followed Sarepta's third-quarter report.
Pipeline strategy supports rating change
Deutsche Bank said it was becoming more constructive on the strategy of using Sarepta's Duchenne muscular dystrophy cash generation to fund pipeline development. The bank also described the company's setup into 2027 as looking decent, citing the potential for improved fundamentals.
The rating change gives investors a more balanced view from a bank that previously expected further downside. The new 18 US dollar target remains an analyst assessment rather than a company forecast, and the report did not change Sarepta's operating outlook.
Sarepta Therapeutics, Inc.
- ISIN: US8036071004
- Ticker: SRPT
- Analyst action: Hold from Sell
- Price target: 18 US dollars, raised from 14 US dollars
- Action date: November 10, 2026
The broader US market environment is covered in Current market reports.
